Loading...

Humacyte, Inc.

HUMAW•NASDAQ
Healthcare
Biotechnology
$0.57
$-0.00(-0.59%)

Humacyte, Inc. (HUMAW) Stock Overview

Explore Humacyte, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 63.7/100

Key Financials

Market Cap468.6M
P/E Ratio-4.30
EPS (TTM)$-3.16
ROE2.86%
Fundamental Analysis

AI Price Forecasts

1 Week$0.65
1 Month$-0.02
3 Months$1.16
1 Year Target$1.17

HUMAW Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Humacyte, Inc. (HUMAW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 60.60, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $1.17.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -4.30 and a market capitalization of 468.6M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Frequently Asked Questions

;